The PHLPP2 phosphatase is a druggable driver of prostate cancer progression

Metastatic prostate cancer commonly presents with targeted, bi-allelic mutations of the PTEN and TP53 tumor suppressor genes. In contrast, however, most candidate tumor suppressors are part of large recurrent hemizygous deletions, such as the common chromosome 16q deletion, which involves the AKT-su...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:J Cell Biol
Main Authors: Nowak, Dawid G., Katsenelson, Ksenya Cohen, Watrud, Kaitlin E., Chen, Muhan, Mathew, Grinu, D’Andrea, Vincent D., Lee, Matthew F., Swamynathan, Manojit Mosur, Casanova-Salas, Irene, Jibilian, Megan C., Buckholtz, Caroline L., Ambrico, Alexandra J., Pan, Chun-Hao, Wilkinson, John E., Newton, Alexandra C., Trotman, Lloyd C.
פורמט: Artigo
שפה:Inglês
יצא לאור: Rockefeller University Press 2019
נושאים:
Research Articles
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC6548123/
https://ncbi.nlm.nih.gov/pubmed/31092557
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1083/jcb.201902048
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים